KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Additional Paid-In Capital

Last Annual Value

238.81M

3-Year CAGR

362%

5-Year CAGR

-13%

10-Year CAGR

-7%

KT

Kalaris Therapeutics Inc Competitors Analysis of Additional Paid-In Capital

KLRS · NASDAQ
CompanyAdditional Paid-In Capital
CAGR 3Y
CAGR 5Y
CAGR 10Y
238.81M
364.9%-14.5%N/A 
452.44M
7.4%5.2%18.2%
0.00
N/AN/AN/A
512.91M
4.4%5.7%N/A
191.29M
33.8%19.8%N/A
469.20M
N/AN/AN/A
1.14B
4.3%3.4%10.7%
748.72M
3.5%5.8%N/A
565.72M
197.2%110.3%N/A
331.75M
6.6%9.1%N/A
322.71M
0.2%N/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66